Results of the dinutuximab beta, bevacizumab, irinotecan and topotecan randomisations of the beacon-neuroblastoma Phase 2 trial by itcc and siopen
Authors
Moreno, L.Weston, R.
Owens, C.
Gray, J.
Barone, G.
Valteau-Couanet, D.
Simon, A. R. S.
Makin, Guy
Vaidya, S.
Gambart, M.
Castel, V.
Van Eijkelenburg, N.
Nysom, K.
Laureys, G.
Ladenstein, R.
Castellano, A.
Gerber, N.
Laidler, J.
Kearns, P.
Wheatley, K.
Affiliation
Valld’Hebron University Hospital,Paediatric Oncology And Haematology,Barcelona, Spain;Issue Date
2022